EA200900214A1 - PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR THE TREATMENT OF TUBERCULOSIS, THE WAY OF ITS OBTAINING AND THE METHOD OF TREATMENT - Google Patents

PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR THE TREATMENT OF TUBERCULOSIS, THE WAY OF ITS OBTAINING AND THE METHOD OF TREATMENT

Info

Publication number
EA200900214A1
EA200900214A1 EA200900214A EA200900214A EA200900214A1 EA 200900214 A1 EA200900214 A1 EA 200900214A1 EA 200900214 A EA200900214 A EA 200900214A EA 200900214 A EA200900214 A EA 200900214A EA 200900214 A1 EA200900214 A1 EA 200900214A1
Authority
EA
Eurasian Patent Office
Prior art keywords
line
pharmaceutical composition
rifabutin
treatment
cell
Prior art date
Application number
EA200900214A
Other languages
Russian (ru)
Other versions
EA013569B1 (en
Inventor
Светлана Эммануиловна ГЕЛЬПЕРИНА
Ольга Олеговна МАКСИМЕНКО
Людмила Витальевна ВАНЧУГОВА
Елена Владимировна ШИПУЛО
Алексей Владимирович ИГНАТЬЕВ
Владимир Евстахиевич БАБИЙ
Original Assignee
Ооо «Научно-Производственный Комплекс "Наносистема"»
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ооо «Научно-Производственный Комплекс "Наносистема"» filed Critical Ооо «Научно-Производственный Комплекс "Наносистема"»
Priority to EA200900214A priority Critical patent/EA013569B1/en
Publication of EA200900214A1 publication Critical patent/EA200900214A1/en
Publication of EA013569B1 publication Critical patent/EA013569B1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области медицины, фармации и нанотехнологии, конкретно к способу получения лиофилизата наносомального рифабутина, солюбилизированного альбумином, методом наноэмульсий, к наносомальной фармацевтической композиции для лечения туберкулеза и заболеваний, опосредованных Helicobacter pilory, представляющей собой лиофилизат рифабутина, солюбилизированного альбумином, характеризующийся средним размером частиц от 4 до 10 нм, а при добавлении фармацевтически приемлемого разбавителя или носителя - пригодную для внутривенного введения нуждающемуся в этом пациенту устойчивую суспензию, характеризующуюся средним размером частиц от 4 до 10 нм, и к способу лечения туберкулеза, включающему внутривенное введение фармацевтической композиции в соответствии с настоящим изобретением в терапевтически эффективном количестве нуждающемуся в этом пациенту. Фармацевтическая композиция по изобретению в сравнении с прототипом может быть получена более простым и доступным способом и не содержит полимеров, что делает ее клиническое применение более безопасным в токсикологическом отношении.The invention relates to the field of medicine, pharmacy and nanotechnology, specifically to a method for producing lyophilized nanosomal rifabutin solubilized with albumin, using nanoemulsions, to a nanosomal pharmaceutical composition for treating tuberculosis and diseases mediated by Helicobacter pilory, which is a lyophilized rifabutin, I am in line with the cell, I am in line with the cell, I’m in the line, I’m in line with the cell, I’m in the line, I’m in the line, I’m I’m in place and I’m in the way I’m in line with the figure, I’m in the line, I’m in the line, I’m in the line, I’m in the line, I’m in the line, I’m in the body, I don’t get it. from 4 to 10 nm, and with the addition of a pharmaceutically acceptable diluent or carrier - suitable for intravenous administering to a patient in need a stable suspension characterized by an average particle size of from 4 to 10 nm, and to a method for treating tuberculosis comprising administering intravenously a pharmaceutical composition in accordance with the present invention in a therapeutically effective amount to the patient in need. The pharmaceutical composition according to the invention in comparison with the prototype can be obtained in a simpler and more accessible way and does not contain polymers, which makes its clinical use safer in toxicological terms.

EA200900214A 2009-02-24 2009-02-24 Pharmaceutical composition of rifabutin for treating tuberculosis and other diseases mediated by helicobacter pylori, method of production thereof and method for treatment thereof EA013569B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA200900214A EA013569B1 (en) 2009-02-24 2009-02-24 Pharmaceutical composition of rifabutin for treating tuberculosis and other diseases mediated by helicobacter pylori, method of production thereof and method for treatment thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA200900214A EA013569B1 (en) 2009-02-24 2009-02-24 Pharmaceutical composition of rifabutin for treating tuberculosis and other diseases mediated by helicobacter pylori, method of production thereof and method for treatment thereof

Publications (2)

Publication Number Publication Date
EA200900214A1 true EA200900214A1 (en) 2010-04-30
EA013569B1 EA013569B1 (en) 2010-06-30

Family

ID=42307738

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900214A EA013569B1 (en) 2009-02-24 2009-02-24 Pharmaceutical composition of rifabutin for treating tuberculosis and other diseases mediated by helicobacter pylori, method of production thereof and method for treatment thereof

Country Status (1)

Country Link
EA (1) EA013569B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012089220A1 (en) * 2010-12-27 2012-07-05 Общество С Ограниченной Ответственностью "Научно-Производственный Комплекс "Наносистема" Method for producing a water-soluble medicinal form of an antibiotic from the group consisting of rifamycins, and composition produced by said method

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023080B1 (en) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Process for preparation of inhalational liposomal form of rifabutin
RU2014120626A (en) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий INSULIN-CONTAINING MEDICINE OF LONG-TERM ACTION
EP3291798A4 (en) * 2015-05-04 2019-01-16 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2308970C1 (en) * 2006-03-10 2007-10-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Antibacterial agent for treatment of intracellular infection
RU2337711C1 (en) * 2007-04-04 2008-11-10 Общество С Ограниченной Ответственностью "Научно-Производственный Комплекс "Наносистема" Agent for bacterial infections treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012089220A1 (en) * 2010-12-27 2012-07-05 Общество С Ограниченной Ответственностью "Научно-Производственный Комплекс "Наносистема" Method for producing a water-soluble medicinal form of an antibiotic from the group consisting of rifamycins, and composition produced by said method

Also Published As

Publication number Publication date
EA013569B1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
Kim et al. Ceria‐based therapeutic antioxidants for biomedical applications
JP2015524444A5 (en)
EP2292235A3 (en) Methotrexate solutions
NZ604029A (en) Methods of treating bladder cancer
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
EA201492010A1 (en) APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS
GB0814302D0 (en) Compounds and methods
RU2010132581A (en) METHODS FOR LUNG DISEASES THERAPY
Lu et al. Hierarchical functional nanoparticles boost osteoarthritis therapy by utilizing joint-resident mesenchymal stem cells
RU2010132580A (en) METHODS AND COMPOSITIONS FOR TREATMENT OF SUBARAHNOIDAL HEMORRHAGE OF CORONARY AND ARTERIAL ANEURISM
RU2008141076A (en) APPLICATION OF THERAPEUTIC HUMAN ALBUMIN FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF PATIENTS AFFECTING COGNITIVE DISORDERS
JP2013542205A5 (en)
EA200900214A1 (en) PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR THE TREATMENT OF TUBERCULOSIS, THE WAY OF ITS OBTAINING AND THE METHOD OF TREATMENT
JP2011190199A5 (en)
RU2015122256A (en) Compositions containing vortioxetine and donepezil
Du Toit et al. Advanced 3D-printed systems and nanosystems for drug delivery and tissue engineering
Ye et al. Macrophage membrane-encapsulated nitrogen-doped carbon quantum dot nanosystem for targeted treatment of Alzheimer's disease: Regulating metal ion homeostasis and photothermal removal of β-amyloid
ATE466574T1 (en) METHODS AND COMPOSITIONS FOR ORAL FTS DELIVERY
JP2014508758A5 (en)
MX353394B (en) APPLICATION OF ß-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT.
RU2012108144A (en) ANTI-CANCER THERAPY DIRECTED AGAINST CANCER STEM CELLS AND CANCER FORMS RESISTANT TO TREATMENT BY MEDICINES
DE602007014193D1 (en) TREATMENT OF PSYCHIATRIC PATIENTS WITH SLEEP DISORDERS AND / OR EXCESSIVE TAGESSLESSNESS WITH PALIPERIDONE
Lu et al. Nanotherapeutics for Alleviating Anesthesia‐Associated Complications
Demina et al. Development strategies and biopharmaceutical aspects of drug delivery systems
Tankl et al. To evaluate role of gabapentin as a preemptive analgesic in the patients undergoing modified radical mastectomy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU